Brokers Set Expectations for GLUE Q3 Earnings

Key Points

• HC Wainwright expects Monte Rosa Therapeutics to report a Q3 2026 loss of $0.45 per share and maintains a “Strong Buy” rating. The firm forecasts full-year 2026 and 2027 losses of $1.81 and $2.22 per share, respectively.
• Monte Rosa’s latest quarter fell short of expectations, with an EPS loss of $0.43 versus the projected $0.38 loss and revenue of $8.97 million versus the $12.91 million consensus.
• Analyst sentiment remains broadly positive, with a “Moderate Buy” consensus rating and an average price target of $28, although shares recently opened at $10.50 and remain well below their 52-week high of $25.77.

Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE - Free Report) - Research analysts at HC Wainwright issued their Q3 2026 earnings estimates for shares of Monte Rosa Therapeutics in a research note issued to investors on Thursday, October 1st. HC Wainwright analyst M. Kapoor expects that the company will earn ($0.45) per share for the quarter. HC Wainwright has a "Strong-Buy" rating on the stock. The consensus estimate for Monte Rosa Therapeutics' current full-year earnings is ($1.23) per share. HC Wainwright also issued estimates for Monte Rosa Therapeutics' Q4 2026 earnings at ($0.48) EPS, FY2026 earnings at ($1.81) EPS, Q1 2027 earnings at ($0.52) EPS, Q2 2027 earnings at ($0.54) EPS, Q3 2027 earnings at ($0.57) EPS, Q4 2027 earnings at ($0.59) EPS and FY2027 earnings at ($2.22) EPS.

Monte Rosa Therapeutics (NASDAQ:GLUE - Get Free Report) last issued its quarterly earnings data on Thursday, August 6th. The company reported ($0.43) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.38) by ($0.05). Monte Rosa Therapeutics had a negative return on equity of 43.31% and a negative net margin of 560.85%.The business had revenue of $8.97 million for the quarter, compared to analysts' expectations of $12.91 million.

Other analysts also recently issued reports about the company. TD Cowen raised Monte Rosa Therapeutics to a "strong-buy" rating in a research note on Monday, August 24th. Weiss Ratings downgraded Monte Rosa Therapeutics from a "sell (d+)" rating to a "sell (d)" rating in a research note on Tuesday, August 11th. Wells Fargo & Company dropped their target price on Monte Rosa Therapeutics from $29.00 to $27.00 and set an "overweight" rating on the stock in a report on Friday, August 7th. Jefferies Financial Group restated a "buy" rating on shares of Monte Rosa Therapeutics in a research note on Monday, July 27th. Finally, Wedbush reaffirmed an "outperform" rating and set a $27.00 price target on shares of Monte Rosa Therapeutics in a report on Wednesday, September 9th. Two analysts have rated the stock with a Strong Buy rating, six have given a Buy rating, one has given a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, the company presently has an average rating of "Moderate Buy" and an average target price of $28.00.

Monte Rosa Therapeutics Stock Performance

Shares of GLUE opened at $10.50 on Monday. Monte Rosa Therapeutics has a fifty-two week low of $7.24 and a fifty-two week high of $25.77. The firm has a 50-day simple moving average of $14.63 and a 200-day simple moving average of $17.72. The company has a market capitalization of $895.75 million, a price-to-earnings ratio of -5.97 and a beta of 1.37.

Hedge Funds Weigh In On Monte Rosa Therapeutics

A number of institutional investors and hedge funds have recently made changes to their positions in GLUE. Allworth Financial LP purchased a new stake in Monte Rosa Therapeutics during the second quarter worth about $30,000. Seven Fleet Capital Management LP purchased a new position in Monte Rosa Therapeutics in the fourth quarter valued at about $63,000. E Fund Management Co. Ltd. acquired a new stake in shares of Monte Rosa Therapeutics during the 2nd quarter valued at approximately $200,000. Pallas Capital Advisors LLC acquired a new stake in shares of Monte Rosa Therapeutics during the 2nd quarter valued at approximately $221,000. Finally, Wealth Effects LLC purchased a new stake in shares of Monte Rosa Therapeutics during the 2nd quarter worth approximately $244,000. 79.96% of the stock is owned by institutional investors and hedge funds.

More Monte Rosa Therapeutics News

Here are the key news stories impacting Monte Rosa Therapeutics this week:

• Positive Sentiment: Encouraging MRT-8102 Phase 1 data: Monte Rosa reported that its NEK7 molecular glue degrader normalized several biomarkers associated with atherosclerotic cardiovascular disease, including IL-1β, HMGB1, calprotectin, S100A12 and SAA. Robust NEK7 degradation was observed across three dose levels, while the treatment was safe and well tolerated over four weeks, with no serious adverse events or apparent increase in infection risk. Monte Rosa Announces Positive MRT-8102 Phase 1 Results
• Positive Sentiment: Pipeline advancement: The company plans Phase 2 studies of MRT-8102 in coronary artery disease, gout and hidradenitis suppurativa. This increases the potential value of the program, although the drug remains in early-stage development. Monte Rosa Plans Mid-Stage Trials
• Positive Sentiment: Analyst support: HC Wainwright initiated coverage with a Buy rating and a $25 price target, then upgraded the shares to Strong Buy, providing a significant bullish signal relative to recent trading levels. HC Wainwright Initiates Coverage
• Neutral Sentiment: Employee equity grants: Monte Rosa granted newly hired employees options covering 86,725 shares and restricted stock units covering 19,150 shares. The awards support hiring but could modestly increase future share dilution; they are not a new capital raise. Monte Rosa Inducement Grants

About Monte Rosa Therapeutics

Monte Rosa Therapeutics, Inc is a clinical-stage biotechnology company focused on developing medicines that selectively eliminate disease-causing proteins. The company uses its proprietary molecular glue degrader platform to identify small molecules that recruit targeted proteins to the cell's natural protein-disposal machinery, potentially addressing proteins that have been difficult to treat with conventional drugs.

Monte Rosa's pipeline is centered primarily on autoimmune and inflammatory diseases, as well as other serious conditions.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.